Bank Of New York Mellon Corp Viridian Therapeutics, Inc.\De Transaction History

Bank Of New York Mellon Corp

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$18.78 - $29.74 $2.86 Million - $4.54 Million	152,553 New	152,553 $4.46 Million
Q3 2022 Nov 14, 2022	BUY	$10.7 - $25.5 $224,518 - $535,066	20,983 Added 30.29%	90,263 $1.85 Million
Q2 2022 Aug 15, 2022	BUY	$9.55 - $19.0 $661,624 - $1.32 Million	69,280 New	69,280 $802,000

181

76.7M

581K

439K

Ticker VRDN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,888,900
Market Cap $795M
Description
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-00...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.